Sepsis inhibits tumor growth in mice with cancer through Toll-like receptor 4-associated enhanced Natural Killer cell activity.

Natural Killer Sepsis Toll-like receptor 4 cancer

Journal

Oncoimmunology
ISSN: 2162-4011
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526

Informations de publication

Date de publication:
Historique:
received: 04 02 2019
revised: 26 06 2019
accepted: 03 07 2019
entrez: 25 10 2019
pubmed: 28 10 2019
medline: 28 10 2019
Statut: epublish

Résumé

Sepsis-induced immune dysfunctions are likely to impact on malignant tumor growth. Sequential sepsis-then-cancer models of tumor transplantation in mice recovering from sepsis have shown that the post-septic immunosuppressive environment was able to promote tumor growth. We herein addressed the impact of sepsis on pre-established malignancy in a reverse cancer-then sepsis experimental model. Mice previously inoculated with MCA205 fibrosarcoma cells were subjected to septic challenges by polymicrobial peritonitis induced by cecal ligation and puncture or endotoxinic shock. The anti-tumoral immune response was assessed through the distribution of tumor-infiltrating immune cells, as well as the functions of cytotoxic cells. As compared to sham surgery, polymicrobial sepsis dampened malignant tumor growth in wild-type (WT) mice, but neither in

Identifiants

pubmed: 31646090
doi: 10.1080/2162402X.2019.1641391
pii: 1641391
pmc: PMC6791422
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

e1641391

Informations de copyright

© 2019 Taylor & Francis Group, LLC.

Références

Int J Cancer. 2002 Oct 10;101(5):415-22
pubmed: 12216068
J Clin Oncol. 2011 Jul 20;29(21):2897-903
pubmed: 21690473
Surgery. 2002 Aug;132(2):365-8
pubmed: 12219036
Cancer Immunol Res. 2016 Apr;4(4):312-22
pubmed: 26817997
Blood. 2010 Jun 3;115(22):4403-11
pubmed: 20130237
Eur J Immunol. 2012 Sep;42(9):2452-8
pubmed: 22740149
Cancer. 1985 Sep 1;56(5):1187-90
pubmed: 3860280
Cell Rep. 2014 Jul 24;8(2):420-9
pubmed: 25017060
Clin Infect Dis. 2019 Feb 15;68(5):717-724
pubmed: 29982318
Br J Cancer. 1999 Dec;81(8):1311-7
pubmed: 10604727
Ann Surg. 1891 Sep;14(3):199-220
pubmed: 17859590
J Immunol. 2006 Jun 1;176(11):6624-30
pubmed: 16709820
Nat Rev Cancer. 2009 Jan;9(1):57-63
pubmed: 19052556
Crit Care Med. 2012 Jan;40(1):55-62
pubmed: 21926606
PLoS One. 2017 Dec 5;12(12):e0188960
pubmed: 29206859
Cancer Res. 1985 Apr;45(4):1657-62
pubmed: 3872168
Nat Rev Immunol. 2017 Feb;17(2):97-111
pubmed: 27748397
Acta Oncol. 2013 Feb;52(2):455-7
pubmed: 22934556
Leukemia. 2006 Jun;20(6):1138-44
pubmed: 16617319
J Innate Immun. 2016;8(3):258-68
pubmed: 26894590
Ann Hematol. 2004 Mar;83(3):189-94
pubmed: 15064869
Nat Rev Nephrol. 2018 Feb;14(2):121-137
pubmed: 29225343
Cancer Epidemiol. 2014 Feb;38(1):56-61
pubmed: 24275260
J Immunol. 2001 May 15;166(10):5878-81
pubmed: 11342601
Science. 2015 Apr 3;348(6230):136-9
pubmed: 25745066
Mol Cancer. 2014 Mar 19;13:60
pubmed: 24642245
Immunology. 2018 Feb;153(2):190-202
pubmed: 29064085
J Immunol. 2017 Feb 1;198(3):1320-1333
pubmed: 28031340
Clin Orthop Relat Res. 1991 Jan;(262):3-11
pubmed: 1984929
Lancet Oncol. 2012 Jun;13(6):607-15
pubmed: 22575588
J Immunol. 2007 Aug 1;179(3):1568-76
pubmed: 17641023
Nat Rev Immunol. 2018 Nov;18(11):671-688
pubmed: 30209347
Cancer Res. 2007 May 1;67(9):4346-52
pubmed: 17483348
Immunobiology. 2017 Jan;222(1):89-100
pubmed: 27349597
PLoS One. 2014 Oct 09;9(10):e109980
pubmed: 25299052
Immunity. 2007 Apr;26(4):503-17
pubmed: 17398124
Surgery. 2018 Mar;163(3):509-514
pubmed: 29229318
Front Immunol. 2017 Oct 26;8:1383
pubmed: 29123526
Science. 2013 Nov 22;342(6161):971-6
pubmed: 24264990
Cancer Biol Ther. 2003 Nov-Dec;2(6):687-93
pubmed: 14688478
Science. 2015 Nov 27;350(6264):1079-84
pubmed: 26541610
Science. 2018 Jan 5;359(6371):91-97
pubmed: 29097494
Cancer Res. 2002 Aug 15;62(16):4696-703
pubmed: 12183428
PLoS One. 2011;6(9):e24407
pubmed: 21931708
J Pathol. 2016 Aug;239(4):473-83
pubmed: 27178223
Front Microbiol. 2018 Jan 23;9:16
pubmed: 29472896
Shock. 2000 Feb;13(2):110-6
pubmed: 10670840
J Immunol. 2008 Dec 15;181(12):8513-20
pubmed: 19050269
Front Immunol. 2015 Sep 23;6:482
pubmed: 26441986
Sci Rep. 2016 Aug 11;6:31490
pubmed: 27511884
Cell. 2010 Mar 19;140(6):883-99
pubmed: 20303878
N Engl J Med. 2014 Jul 24;371(4):380-3
pubmed: 25054723
J Invest Dermatol. 2016 Apr;136(4):862-865
pubmed: 26743601
Oncogene. 2011 May 26;30(21):2475-84
pubmed: 21278795
Science. 2013 Nov 22;342(6161):967-70
pubmed: 24264989
J Exp Med. 2002 Jul 1;196(1):119-27
pubmed: 12093876

Auteurs

Clara Vigneron (C)

Institut Cochin, INSERM U1016, CNRS UMR8104, Paris, France.
Université Paris Descartes, Paris, France.

Adrien Mirouse (A)

Institut Cochin, INSERM U1016, CNRS UMR8104, Paris, France.
Université Paris Descartes, Paris, France.

Hamid Merdji (H)

Institut Cochin, INSERM U1016, CNRS UMR8104, Paris, France.
Université Paris Descartes, Paris, France.

Christophe Rousseau (C)

Institut Cochin, INSERM U1016, CNRS UMR8104, Paris, France.
Université Paris Descartes, Paris, France.

Clément Cousin (C)

Institut Cochin, INSERM U1016, CNRS UMR8104, Paris, France.
Université Paris Descartes, Paris, France.

Fanny Alby-Laurent (F)

Institut Cochin, INSERM U1016, CNRS UMR8104, Paris, France.
Université Paris Descartes, Paris, France.

Jean-Paul Mira (JP)

Institut Cochin, INSERM U1016, CNRS UMR8104, Paris, France.
Université Paris Descartes, Paris, France.
Médecine Intensive & Réanimation, hôpital Cochin, Hôpitaux Universitaires Paris Centre, Assistance Publique - Hôpitaux de Paris, Paris, France.

Jean-Daniel Chiche (JD)

Institut Cochin, INSERM U1016, CNRS UMR8104, Paris, France.
Université Paris Descartes, Paris, France.
Médecine Intensive & Réanimation, hôpital Cochin, Hôpitaux Universitaires Paris Centre, Assistance Publique - Hôpitaux de Paris, Paris, France.

Jean-François Llitjos (JF)

Institut Cochin, INSERM U1016, CNRS UMR8104, Paris, France.
Université Paris Descartes, Paris, France.
Médecine Intensive & Réanimation, hôpital Cochin, Hôpitaux Universitaires Paris Centre, Assistance Publique - Hôpitaux de Paris, Paris, France.

Frédéric Pène (F)

Institut Cochin, INSERM U1016, CNRS UMR8104, Paris, France.
Université Paris Descartes, Paris, France.
Médecine Intensive & Réanimation, hôpital Cochin, Hôpitaux Universitaires Paris Centre, Assistance Publique - Hôpitaux de Paris, Paris, France.

Classifications MeSH